Bioconversion, Pharmacokinetics, and Therapeutic Mechanisms of Ginsenoside Compound K and Its Analogues for Treating Metabolic Diseases

    February 2024 in “ Preprints.org ”
    Md. Niaj Morshed, Reshmi Akter, Imran Mahmud, Md Rezaul Karim, Safia Iqbal, Md. jakaria Islam, Se Chan Kang, Deok‐Chun Yang
    Studysummary This review discusses the pharmacology and potential therapeutic effects of rare ginsenoside compound K on metabolic disorders but presents no new clinical results, highlighting the need for further studies on its bioavailability and toxicity. Our plain-language summary of this paper — not a Tressless recommendation.
    Ginsenoside Compound K (CK), derived from Korean ginseng, shows promise in treating metabolic diseases such as type 2 diabetes, obesity, and nonalcoholic fatty liver disease due to its pharmacological properties, including anti-inflammatory and anti-diabetic effects. CK acts on key metabolic pathways, influencing PPARγ and AMPK, which are crucial in managing these disorders. Despite its potential, CK's development is hindered by limited data on its therapeutic use and documented cytotoxicity. Studies indicate CK is generally safe and well-tolerated, with mild adverse effects like diarrhea and stomachache. However, concerns about hepatotoxicity and nephrotoxicity remain, necessitating further research. CK is not abundant in natural ginseng, prompting the use of enzymatic and microbial biotransformation methods to enhance its production. The document emphasizes the potential of CK as a treatment and preventive measure for metabolic disorders, supported by various studies on animal models.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results